29 November 2024
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Results of 2024 Annual General Meeting
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at 10:00 am at the offices of Aptamer Group, Windmill House, Innovation Way, York, YO23 1LR, all Resolutions were duly passed.
Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 5 November 2024 and the full poll results will be made available on the Aptamer website later today.
- Ends -
For further information, please contact:
| Aptamer Group plc Arron Tolley, Chief Executive Officer | +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Adam Dawes | +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
| Northstar Communications Limited - Investor Relations Sarah Hollins | +44 (0) 113 730 3896 |
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers. Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
